Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

119 results about "Renal glomerulus" patented technology

Renal glomerulus. a small convoluted mass of capillaries, a network of vascular tufts, encased in the malpighian or Bowman's capsule. The glomerulus is an integral part of the nephron, the basic unit of the kidney. Each nephron is capable of forming urine by itself, and each kidney has many nephrons.

Metabolic characteristic-based medicine dosage optimization method for chronic diseases of old people

The invention relates to the technical field of treatment of chronic diseases of old people, and discloses a metabolic characteristic-based medicine dosage optimization method for chronic diseases of old people. The method comprises the following steps: acquiring drug metabolism parameters (including a plasma concentration peak value, a half-life period curve and the like) and organ function data (including a hepatocyte metabolism rate, a glomerular filtration rate and the like) of a plurality of monitoring nodes, arranging the drug metabolism parameters and the organ function data into a time sequence input vector, and extracting a dynamic feature vector by using a time convolution network and an adaptive filter network; performing feature crossing, pharmacokinetic constraint correction and feature enhancement processing, performing fusion to generate a joint feature vector, inputting the joint feature vector into a dose decision model to obtain an adjustment coefficient, and generating a drug dose interval with a safety threshold in combination with a historical drug use record. According to the method, multi-dimensional data integration and dynamic modeling are realized, the accuracy and safety of chronic disease medication of old people are improved, and the method is suitable for individualized treatment.
Owner:SECOND MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL

Application of ADAM10 or ADAM17 in preparation of medicine for preventing / treating membranous nephropathy

The invention discloses application of ADAM10 or ADAM17 serving as a target spot in preparation of a medicine for preventing / treating membranous nephropathy and application of an ADAM10 or ADAM17 inhibitor in preparation of the medicine for preventing / treating membranous nephropathy. The invention finds that ADAMs mediate the deposition process of immune complexes of autoantigens such as PLA2R1 of membranous nephropathy, and enzyme digestion of podocytes to transmembrane autoantigen proteins such as PLA2R can be inhibited by performing targeted intervention on the activity of ADAMs, especially the activity of ADAM10 and ADAM17, so that immune complexes deposited in glomerulus are reduced, the podocyte damage of membranous nephropathy is improved, and the therapeutic effect is achieved.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Multi-scale Mama and dynamic sampling-based glomerular segmentation method

The invention discloses a glomerular segmentation method based on multi-scale Mama and dynamic sampling, and relates to the technical field of medical images. According to the method, the input multi-scale features are efficiently represented by using a continuous state transition mechanism, the structural association information extraction capability among different scales is enhanced, in addition, the problem of geometric distortion in dynamic sampling is solved by introducing position coding into the dynamic sampling method and adding position constraint information, and the dynamic sampling efficiency is improved based on a U-Net model. An MS-Mama module is gradually added in the encoder stage, and an existing bilinear interpolation method is replaced by a position sensing dynamic sampling module; and then, serialized representation is performed on multi-scale features based on a selective state space mechanism, the dependence of Mama on specific scale features is reduced, the ability of extracting heterogeneous morphological features of lesion glomerulus is enhanced, the boundary positioning precision of lesion glomerulus is enhanced by adding position constraint information, and the geometric distortion problem in dynamic sampling is solved.
Owner:CHONGQING UNIV OF TECH

Phosphatidylcholine gold nano CT probe as well as preparation method and application thereof

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

A method and system for constructing a glomerular filtration rate estimation model

A method and system for constructing a glomerular filtration rate estimation model, including: step 1: performing mRMR feature selection on the original data set, screening out the independent variable features, and using the transformed data set as the basic data set for subsequent modeling; step 2: constructing two linear regression models on the basic data set; step 3: performing sampling with replacement on the basic data set, and removing duplicate samples; step 4: training the set model on the N sampled data sets after removing duplicates in step 3, and obtaining its parameters: obtaining N temporary local models, and performing multivariate linear regression modeling on the N sampled data sets after removing duplicates according to the above two forms obtained in step 2; step 5: constructing a global model, using the average of the local model parameters obtained in step 4 as the parameters of the global model, and the obtained global model is the constructed glomerular filtration rate estimation model. The present invention models data for a specific population and obtains a GFR estimation model that is more suitable for the specific population.
Owner:XIDIAN UNIV

Cell detection method and system for glomerular pathological section image

The invention relates to the technical field of glomerular pathological section cell detection, and discloses a cell detection method and system for a glomerular pathological section image, and the method and system are used for dynamically adjusting a detection threshold value based on the morphological characteristics of cells in the glomerular pathological section image so as to solve the problem that the cell boundary is fuzzy. The contrast enhancement degree is regulated and controlled according to the non-uniform illumination characteristic of the image, so that the detail loss area in the low-quality image is optimized; adjusting classification model parameters according to different types of glomerular lesion features so as to reduce the probability of occurrence of false detection and missing detection; and setting the number of iterations of the segmentation algorithm according to the cell overlapping degree to realize complete separation of dense cells. Through the scheme of the embodiment of the invention, the problem of how to regulate and control the detection threshold value according to the morphological characteristics of the cells in the glomerular pathological section so as to solve the problem of fuzzy cell boundary can be solved, and the phenomena of false detection and missing detection are reduced by taking the lesion specific marker in the training data set as input guidance.
Owner:田咏志

Application of poecilobdella manillensis in preparation of medicine for treating renal injury

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.
Owner:YUNNAN SANJIANG HERBAL MEDICINE CO LTD

SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USE THEREOF

The present disclosure provides at least one compound, tautomer, deuterated derivative, or pharma- ceutically acceptable salt selected from compounds of formula I, tautomers thereof, deuterated derivatives of the compounds or tautomers, and pharma- ceutically acceptable salts of any of the foregoing, compositions comprising them, and methods of using them, including use in the treatment of APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD). JPEG2024544060000117.jpg5039
Owner:VERTEX PHARMACEUTICALS INC

System and method for accurately segmenting EdgeAttenNet glomerular image based on camouflage target detection

The invention discloses an EdgeAttenNet glomerular image accurate segmentation system and method based on camouflage target detection. A camouflage target detection technology is innovatively applied to the field of glomerular segmentation for the first time. The system includes a feature extraction module, an attention-guided boundary module (AGBM), an edge-guided feature enhancement module (EFEM), and an adaptive fusion context module (AFCM). According to the EdgeAttenNet, through the synergistic effect of a plurality of innovative modules, the problems of detail loss, boundary fuzziness and the like in a traditional method are effectively solved, and the accuracy of glomerular segmentation and the boundary positioning precision are remarkably improved. The system combines the cross entropy loss and the Dice loss, and realizes the balance between the pixel level classification accuracy and the region overlapping degree. The EdgeAttenNet enhances the interpretability and adaptability of the model while improving the segmentation performance, is suitable for medical image segmentation, provides reliable technical support for glomerular pathology analysis, and has important clinical application value.
Owner:SHENYANG UNIVERSITY OF TECHNOLOGY

Clazakizumab in the Treatment of Chronic Antibody-Mediated Rejection of Organ Transplant

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab. Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.
Owner:CEDARS SINAI MEDICAL CENT

Pathology grading method and device, storage medium and computer program product

The invention discloses a pathology grading method and device, a storage medium and a computer program product, and relates to the technical field of medical image processing.The pathology grading method comprises the steps that a light microscope image of renal biopsy is obtained, a preset glomerulus recognition model is used for detecting the light microscope image, and slice images of all glomerulus are obtained; according to the slice image, determining a proportion result of each type of glomerulus in the light microscope image; and determining a pathology grading result according to the proportion result and a preset pathology grading rule. According to the method and the device, the glomerulus in the biopsy image is automatically identified and classified, and automatic classification is carried out according to the clinical pathology classification standard, so that the workload of a clinician in pathology classification is reduced, and the accuracy and the efficiency of pathology classification are improved.
Owner:SUN YAT SEN UNIV

Traditional Chinese medicine composition aiming at hypoyin and taiyin combined disease, preparation, application and preparation method

The invention relates to the field of traditional Chinese medicine, and particularly provides a traditional Chinese medicine composition aiming at a hypoyin and taiyin combined disease, a preparation, application and a preparation method, and the composition is prepared from the following components: ephedra, radix aconiti carmichaeli, poria cocos, rhizoma atractylodis macrocephalae, cassia twig, liquorice, semen cuscutae, leech, earthworm, mole cricket, aspongopus, mantis egg-case, radix pseudostellariae and astragalus membranaceus. The ephedra-monkshood-licorice decoction and the Linggui-curcuma zedoary-licorice decoction have the effects of warming yang and relieving exterior syndrome, tonifying spleen and clearing damp; radix astragali and radix pseudostellariae are used for tonifying qi and dredging Semen cuscutae and mantis egg-case have the effects of tonifying kidney and inducing astringency; leech and lumbricus activate blood, eliminate diseases and dredge collaterals; aspongopus and mole cricket regulate qi, dredge collaterals and promote urination All the medicines are combined to jointly achieve the effects of tonifying qi, activating blood, inducing diuresis, dispersing blood stasis, eliminating diseases, dredging collaterals, smoothing blood circulation and removing blood stasis and complexing, the immune function of a body can be improved, the hypercoagulable state of blood of a patient suffering from diabetic nephropathy can be solved, a filtration barrier of glomerulus can be repaired and improved, and therefore the purposes of removing proteinuria and improving the renal function are achieved.
Owner:SHANGHAI SIXTH PEOPLES HOSPITAL JINSHAN BRANCH (JINSHAN DISTRICT CENT HOSPITAL AFFILIATED TO SHANGHAI HEALTH MEDICAL COLLEGE SHANGHAI JINSHAN DISTRICT CENT HOSPITAL)

Early-stage amyloid nephropathy recognition and diagnosis method based on deep learning

The invention relates to a deep learning-based early-stage amyloidosis nephropathy identification and diagnosis method, belongs to the technical field of amyloidosis nephropathy identification, and solves the problem that early-stage amyloidosis cannot be accurately identified in the prior art. The method comprises the following steps: acquiring kidney pathological section images of different individuals to construct a training sample set; constructing a link model comprising a first region segmentation model, a second region segmentation model and a third region segmentation model; the first region segmentation model is used for segmenting a cortex region in the pathological image; the second region segmentation model is used for segmenting a glomerular region; the third region segmentation model is used for identifying amyloidosis of a glomerular region; training the link model based on the training sample set to obtain a trained link model; and inputting a to-be-identified kidney pathological section image into the trained link model to identify whether amyloidosis exists or not. And efficient and accurate early-stage amyloidosis identification is realized.
Owner:PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE)

Light microscope kidney pathological image analysis method based on artificial intelligence

The invention provides a light microscope kidney pathological image analysis method based on artificial intelligence, and relates to the technical field of image recognition, and the method comprises the steps: obtaining a multi-mode light microscope kidney pathological image; performing positioning analysis on the glomerular structure of the multi-mode light microscope kidney pathological image by using the target detection network to obtain a position prediction result; classifying the position prediction result by using a classification network to obtain a classification result; utilizing a semantic segmentation network to perform pathological feature quantitative extraction on the complete glomerulus in the classification result to obtain a quantitative pathological index; and performing multi-level feature fusion on the classification result and the quantitative pathological indexes, and analyzing the obtained multi-level fusion features by using a multi-instance learning network of hierarchical attention to obtain a multi-modal light microscope kidney pathological image analysis result, thereby completing analysis of the light microscope kidney pathological image. The problem that an existing artificial intelligence method is difficult to accurately quantify the light microscope kidney pathological image is solved.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Application of pharmaceutical composition in preparation of nephropathy drugs

The invention discloses application of a pharmaceutical composition in preparation of a medicine for treating nephropathy, the nephropathy is at least one of membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and the pharmaceutical composition belongs to the technical field of pharmacy. The pharmaceutical composition is prepared from the following flavonoid components in a mass ratio: the mass ratio of the gossypothelin-8-O-beta-D-glucuronide to the hyperoside to the isoquercitrin to the myricetin to the quercetin-3 '-O-glucoside is 10 to (3.0 to 20) to (2.0 to 18) to (0.2 to 6.0) to (1 to 20). The pharmaceutical composition has obvious effects of preventing and / or treating membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and has relatively good safety.
Owner:SUZHONG PHARMACEUTICAL GROUP CO LTD +2

Basilar membrane sampling method based on glomerular capillary branch characteristics

PendingCN121074003AImage analysisRenal glomerulusGlomerular basement membrane
The invention provides a basement membrane sampling method based on glomerular capillary branch characteristics, and relates to the technical field of image recognition, and the method comprises the steps: employing the center and radius of a glomerular region, carrying out the analysis of the mesangial crossing condition of a basement membrane, obtaining a mesangial crossing result, carrying out the region division and sampling window size calculation, and carrying out the calculation of the size of a sampling window. Obtaining a plurality of sectors and corresponding window areas; random sampling is carried out in the sectors to obtain candidate center points; analyzing the candidate center point based on the window area, if the sampling is not qualified, performing failure retry and annealing strategy to adjust the window, and resampling; otherwise, obtaining a qualified window; and combining all qualified windows to obtain a basement membrane sampling result, and completing the basement membrane sampling based on the glomerular capillary branch characteristics. According to the method, the problem of how to perform balanced, low-deviation, reproducible and efficient sampling and labeling on the glomerular basement membrane under the anatomical priori constraint in the light microscope glomerular pathological image is solved.
Owner:SICHUAN UNIV

Method for ex VIVO measuring glomerular filtration rate in a subject

PCT designated stage expiredWO2024256617A1SensorsUrological function evaluationExcretory phaseRenal glomerulus
The present invention relates to a method for ex vivo measuring glomerular filtration rate (GFR) of a subject to whom a contrast agent has been administered, and to whom computed tomography (CT) or magnetic resonance imaging (MRI) including an excretory phase, an unenhanced phase, an arterial phase, and a nephrographic or a venous portal phase has been performed, said method comprising the step of calculating the clearance of the contrast agent from CT or MRI data using manual, automated or semi-automated segmentation software, thereby obtaining a measured GFR.
Owner:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (APHP)

Kidney active fusion proteins and methods of treatment using the same

PCT designated stageWO2026135714A1Connective tissue peptidesPeptide/protein ingredientsSegmental glomerulosclerosisRenal glomerulus
Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.
Owner:ALEXION PHARMACEUTICALS INC

AAGN disease metabolism marker, kit and application of AAGN disease metabolism marker

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

System and method for rapid assessment of renal function

A system and method for diagnosing a patient's renal function, the method comprising delivering a first tracer agent, transmucosally applying a first excitation light to the first tracer agent at the first monitoring site, transmucosally receiving a first fluorescent light emitted from the first tracer agent at the first monitoring site, transforming the received first fluorescent light to produce a first fluorescence signal, processing the first fluorescence signal to determine a first decay rate, and processing the first decay rate of the first fluorescent light to determine a glomerular filtration rate of the patient.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

Biomarkers for diagnosing diabetic nephropathy and use thereof

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Application of pharmaceutical composition in treating diabetic nephropathy

The present invention relates to a pharmaceutical composition for treating diabetic nephropathy, wherein the composition comprises a screened cobra cardiotoxin having a specific amino acid sequence. The diabetic nephropathy (DKD) refers to chronic kidney disease caused by diabetes. The composition can reduce the urine albumin / creatinine ratio (UACR) of diabetic nephropathy and improve the estimated glomerular filtration rate (eGFR).
Owner:JIANGSU HAOMO PHARM BIOTECHNOLOGY CO LTD

Traditional Chinese medicine preparation for preventing and treating hyperuricemia and preparation method thereof

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine preparation for preventing and treating hyperuricemia, which is prepared from the following raw materials by weight: 5-20g of gynostemma pentaphyllum, 10-20g of selaginella doederleinii hieron, 5-15g of berchemia lineate, 5-15g of parthenocissus parvifolia, 12-15g of lotus leaf, 12-15g of cassia seed, 12-15g of white paeony root and 3-6g of raw liquorice. The traditional Chinese medicine composition has no obvious influence on the normal blood sugar level, has stable hypoglycemic activity when being used by diabetes patients, cannot reduce the normal blood sugar state when being taken, can reduce the uric acid level, protect the kidney, improve the glomerular filtration rate and promote uric acid excretion, and can effectively treat, inhibit or prevent hyperuricemia.
Owner:NANJING BREEZE BIOTECHNOLOGY CO LTD

Application of histone methyltransferase EZH2 as therapeutic target for podocyte senescence and injury of diabetic nephropathy

The invention provides application of histone methyltransferase EZH2 as a therapeutic target of diabetic nephropathy podocyte senescence and injury, and relates to the technical field of biological medicine. It is found that the expression level of EZH2 in podocyte under the high glucose condition is remarkably increased, and conditions are provided for taking EZH2 as a biomarker for diagnosing or evaluating diabetic nephropathy podocyte damage and senescence. Subsequently, it is verified that podocyte damage of db / db mice can be remarkably improved, proteinuria of the db / db mice can be reduced, pathological damage of kidneys can be relieved, glomerular senescence of the db / db mice can be delayed, damage and senescence of podocytes under the high-glucose condition can be remarkably improved, the purpose of protecting the kidneys is achieved, the development of diabetic nephropathy is delayed, and the development of diabetic nephropathy is delayed. Therefore, the EZH2 can be used as a potential target for treating diabetic nephropathy.
Owner:ZHENGZHOU UNIV

Fragment omics in urine and plasma

The fragment omics features provide various properties of a sample (e.g., urine or plasma) and / or a subject. The relative contribution or enrichment of clinically relevant DNA (e.g., the type of renal and non-renal urine cfDNA) is provided utilizing the fragment omics characteristics of urine free DNA. Such measurements may be used to reflect glomerular permeability and to monitor various diseases, such as kidney abnormalities. The fragmenomics characteristics may include corrected urine DNA concentration, length, terminal motif of the urine DNA molecule, and cfDNA molecules from open chromatin regions (OCRs) of one or more tissues. Furthermore, the nuclease activity or other fragmentation process of the cfDNA is determined based on the relative contributions associated with different cfDNA cleavage profiles, which are also used to determine the contribution, pathological grade and gestational age of the cfDNA from the tissue.
Owner:CENT FOR NOVOSTICS

Composition for preventing or treating lupus comprising recombinant stable galectin 9 protein

The present invention relates to a composition for the prevention or treatment of lupus or glomerulonephritis, comprising a recombinant stable galectin 9 protein, and specifically, the recombinant stable galectin 9 protein of the present invention can be used in the prevention or treatment of systemic lupus erythematosus; the present invention shows safety in an SLE animal model, reduces skin lesions, lymphadenectasis and proteinuria caused by lupus, alleviates lupus nephritis and glomerulonephritis, reduces the concentration of anti-dsDNA antibodies in plasma, and provides a new means for treating lupus nephritis and glomerulonephritis. Therefore, the recombinant stable galectin 9 protein of the present invention can be effectively used as an active ingredient of a composition for preventing or treating lupus or glomerulonephritis.
Owner:GBIOLOGICS INC

Method for constructing diagnosis model of glomerular crescent body of lupus nephritis patient

The invention belongs to the field of medicine models, and provides a method for constructing a diagnosis model of glomerular crescent bodies of lupus nephritis patients. Comprising the steps of target collection data acquisition, statistical data analysis, inter-group comparison, biological index importance calculation and screening, candidate variable secondary screening, crescent body diagnosis model construction and crescent body diagnosis column graph construction. According to the method, the XGBoost algorithm is utilized to perform initial screening on the pre-prepared variables, and then the unconditional logistic gradual forward regression analysis is utilized to perform secondary screening, so that reliable screening of the crescent marker variables is realized, and in addition, the screening efficiency of the variables is improved; by converting the crescent body diagnosis model into the crescent body diagnosis column diagram, the crescent body diagnosis process is simplified, and the intuition of the model is improved.
Owner:SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)

Application of CLK2 inhibitor in preparation of medicine for treating IgA nephropathy

The invention belongs to the technical field of disease drug treatment, and particularly relates to application of a CLK2 inhibitor in preparation of a drug for treating IgA nephropathy. The CLK2 inhibitor (such as ganoderic acid A methyl ester) can be used for remarkably reducing the levels of 24h UTP, 24h mAlb, BUN and Scr of an IgA nephropathy model and IGA deposition in glomerulus, so that the aim of effectively treating the IgA nephropathy is fulfilled.
Owner:BEIJING UNIV OF CHINESE MEDICINE